Results 61 to 70 of about 949 (151)
MedComm, Volume 6, Issue 12, December 2025.Alcohol‐related (ALD) and metabolic dysfunction‐associated (MASLD) steatotic liver disease, while initiated by distinct etiologies (ethanol vs. metabolic stress), converge on shared core pathogenic pathways that drive progression. These include dysregulated lipid metabolism, programmed cell death, cellular senescence, gut dysbiosis, and immune ...
Yupin Tan +3 more
wiley +1 more source
Healing Effects of Saroglitazar Gel in Thermally Induced Burn in Rats [PDF]
Al-Anbar Medical JournalBackground: Burn is associated with several consequences, including an increased incidence of infection, extended duration of hospitalization, and an increased mortality rate.
Aram Ibrahim +4 more
doaj +1 more source
Fatty liver - Current and future treatment: A narrative review
Apollo Medicine, 2021 A holistic approach is required for managing patients with nonalcoholic fatty liver disease (NAFLD). Lifestyle interventions and medical management of metabolic risk factors currently form the cornerstone of NAFLD management.
Arka De, Ajay Duseja
doaj +1 more source
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
Indian Journal of Endocrinology and Metabolism, 2014 A triad of high triglycerides, low high-density lipoprotein (HDL) cholesterol, and elevated small dense low-density lipoprotein particles occurring in a patient with type 2 diabetes is referred to atherogenic diabetic dyslipidemia (ADD).
Srinivasa P Munigoti, C V Harinarayan
doaj +1 more source
JGH Open, Volume 9, Issue 9, September 2025.ABSTRACT Background and Objective Seladelpar is an oral, once‐daily medication that improves cholestasis through its selective peroxisome proliferator‐activated receptor (PPAR‐δ) agonism. It shows promising efficacy in treating primary biliary cholangitis (PBC) patients.
Mohamed Abuelazm +7 more
wiley +1 more source
, 2023 Saroglitazar is a novel medication for dyslipidemia, but its specific effects remain unclear. Therefore, we performed a systematic review and meta-analysis to assess the efficacy and safety of saroglitazar for managing dyslipidemia.
Antonio da Silva Menezes Junior +9 more
core +1 more source
Epigenetic Regulation of Aging and its Rejuvenation
MedComm, Volume 6, Issue 9, September 2025.This article provides an overview of the epigenetic mechanisms and key targets involved in aging, including DNA methylation, histone modifications, chromatin remodeling, and changes in noncoding RNAs. It also introduces various intervention strategies aimed at reversing epigenetic changes to delay aging and treat diseases.
Yongpan An +11 more
wiley +1 more source
A comprehensive review on adaptive plasticity and recovery mechanisms post‐acquired brain injury
Neuroprotection, Volume 3, Issue 3, Page 226-252, September 2025.This figure illustrates the dynamic process of neurogenesis following brain injury, focusing on the roles of neural stem and progenitor cells at the injury site. Key mechanisms include axonal sprouting, synaptogenesis, dendritic remodeling, and brain‐derived neurotrophic factor signaling via TrkB receptors.
Ravi Kumar Rajan
wiley +1 more source
Life and ScienceObjective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treating diabetic dyslipidemia. Study Design: Comparative cross-sectional study.
Bakhtawar Farooq +4 more
doaj +1 more source
Suppression of TGF-β/Smad3 signaling pathway by Capparis spinosa and quercetin in a rat model of nonalcoholic steatohepatitis [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): Liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), pose significant global public health challenges.
Reza Afarin +4 more
doaj +1 more source